Blue Granite Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Blue Granite Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$834K	Sell	44,014 -60,499	-58%	-$910K	0.61%	18
2017 Q3	$1.84M	Buy	104,513 +25,000	+31%	+$563K	1.27%	28
2017 Q2	$2.64M	Buy	79,513 +15,913	+25%	+$493K	1.71%	28
2017 Q1	$2.04M	Buy	63,600 +10,100	+19%	+$345K	1.34%	36
2016 Q4	$1.94M	Buy	+53,500	New	+$2.14M	1.38%	35

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Blue Granite Capital's TEVA Position: Q4 2017 in Review

Blue Granite Capital reduced its Teva Pharmaceuticals (TEVA) stake by 58% in Q4 2017, selling an estimated $910K and leaving 44,014 shares worth $834K. The position accounts for 0.61% of the portfolio, ranked #18.

Blue Granite Capital first reported a position in TEVA in Q4 2016 and has held it in 5 quarters since. The position peaked at $2.64M in Q2 2017. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

Blue Granite Capital held 44,014 shares of Teva Pharmaceuticals worth $834K as of Q4 2017.
Blue Granite Capital sold 60,499 Teva Pharmaceuticals shares in Q4 2017, an estimated $910K.
Teva Pharmaceuticals made up 0.61% of Blue Granite Capital's portfolio in Q4 2017, its #18 holding.
Blue Granite Capital first reported a position in Teva Pharmaceuticals in Q4 2016 and has held it in 5 quarters since.
Blue Granite Capital's Teva Pharmaceuticals position peaked at $2.64M in Q2 2017.
507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Blue Granite Capital's 13F filing for Q4 2017, filed 14 Feb 2018.